尿多酸肽治疗低/中危骨髓增生异常综合征患者贫血改善的疗效观察  

Efficacy of uroacitides in treating anemia patients with low/intermediate-Ⅰ risk myelodysplastic syndrome

作　　者：陈建新[1] 王轩[1] 于阳[1] 周越[1] 包芳[1] 李佳[1] 吴学宾[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院血液科,北京100038

出　　处：《中国新药杂志》2012年第5期502-504,共3页Chinese Journal of New Drugs

摘　　要：目的:观察尿多酸肽(CDA-2)治疗低/中危骨髓增生异常综合征(MDS)的贫血改善疗效。方法:确诊为低/中危-Ⅰ的MDS患者12例,接受连续2～4疗程以CDA-2为主的治疗后,观察总疗效、贫血改善的疗效及不良反应。结果:12例患者中,6例贫血改善,其中显效4例(33.3%),有效2例(16.7%),总有效率50.0%,平均起效时间30.1 d;不良反应包括轻度恶心6例(50.0%),轻度水肿4例(33.3%)。结论:以CDA-2为主的治疗对改善低/中危-ⅠMDS患者的贫血有较好的疗效,不良反应较轻。Objective： To observe the efficacy of uroacitides（CDA-2） in treating anemia patients with low/intermediate-Ⅰ risk myelodysplastic syndrome（MDS）.Methods： Twelve patients with low/intermediate-Ⅰ risk MDS received CDA-2 combined with other drugs for 2~4 cycles.The overall response,improvement of anemia and adverse reactions were analyzed.Results： Six patients had improved hemoglobin levels giving an overall response rate of 50.0%,among which 4（33.3%） cases showed excellent efficacy and 2（16.7%） cases showed efficacy.The average time of response onset was 30.1 days.The adverse reactions were slightly nausea in 6（50.0%） patients and edema in 4（33.3%） patients.Conclusion： CDA-2 can improve the anemia of low/intermediate-Ⅰ risk MDS patients with mild adverse reactions.

关 键 词：尿多酸肽 骨髓增生异常综合征 疗效 贫血 DNA甲基转移酶抑制剂 

分 类 号：R552[医药卫生—血液循环系统疾病]